- 主题发起人 vickyzyd
- 发布时间 2014-03-12
TransEnterix (NYSE:TRXC) today posted third quarter earnings that beat expectations on Wall Street.
The Research Triangle Park, N.C.-based company posted losses of $20.2 million, or 10¢ per share, on sales of $5.4 million for the three months ended September 30, seeing losses shrink 47.5% while sales grew nearly 3000% compared with the same period during the previous year
Adjusted to exclude one-time items, losses per share were 6¢, just ahead of the 7¢ loss-per-share consensus on Wall Street where analysts expected to see sales of $5.3 million, which TransEnterix topped.
“We are proud of the progress we made during the third quarter, as we continued to drive adoption of the Senhance System by executing on our sales and marketing strategy and continuing to develop the capabilities of the Senhance System to deliver on our vision of digital laparoscopy. We are focused on driving the global adoption of the Senhance System by increasing the applicability of the system for a wider range of surgeons, patients and geographies,” prez & CEO Todd Pope said in a press release.
The Research Triangle Park, N.C.-based company posted losses of $20.2 million, or 10¢ per share, on sales of $5.4 million for the three months ended September 30, seeing losses shrink 47.5% while sales grew nearly 3000% compared with the same period during the previous year
Adjusted to exclude one-time items, losses per share were 6¢, just ahead of the 7¢ loss-per-share consensus on Wall Street where analysts expected to see sales of $5.3 million, which TransEnterix topped.
“We are proud of the progress we made during the third quarter, as we continued to drive adoption of the Senhance System by executing on our sales and marketing strategy and continuing to develop the capabilities of the Senhance System to deliver on our vision of digital laparoscopy. We are focused on driving the global adoption of the Senhance System by increasing the applicability of the system for a wider range of surgeons, patients and geographies,” prez & CEO Todd Pope said in a press release.
Senseonics Holdings (NYSE: SENS) reported Q3 EPS of ($0.18), $0.04 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $5.2 million versus the consensus estimate of $5.16 million.
“The third quarter was a particularly exciting time for Senseonics with the U.S. launch of the Eversense system. Feedback from our first users has been exceptional across both patient and healthcare professional communities,” said Tim Goodnow, President and Chief Executive Officer of Senseonics. “As we look ahead, we are pleased with the early progress we are making to establish reimbursement and broaden patient and physician access to Eversense. Simultaneously, we are continuing to develop our clinical pipeline. We look forward to expanding our reach as we bring this life changing technology to people with diabetes.”
“The third quarter was a particularly exciting time for Senseonics with the U.S. launch of the Eversense system. Feedback from our first users has been exceptional across both patient and healthcare professional communities,” said Tim Goodnow, President and Chief Executive Officer of Senseonics. “As we look ahead, we are pleased with the early progress we are making to establish reimbursement and broaden patient and physician access to Eversense. Simultaneously, we are continuing to develop our clinical pipeline. We look forward to expanding our reach as we bring this life changing technology to people with diabetes.”
机器销售量不行，目前打不开市场，这行太烧钱了，开盘药丸
哈哈好牛，回来了
也有道理
GE是不是快破产了？美股可没跌停板啊！
